Home

Disease management

Read time: 4 min

Congress highlights

Mortality excess in schizophrenia: can we close the gap?

People with first-episode psychosis who had no antipsychotic medication treatment had a five-year...

Read time: 3 min

Congress highlights

Networking - a brilliant take off or a flight of fancy?

You would think that the behaviour of a flock of starlings would have little to do with mental...

Read time: 3 min

Bouncing back - Resilience in schizophrenia

Can we improve resilience in patients with schizophrenia to help recovery? Resilience is...

Alzheimer's Disease

Read time: 3 min

Agitation should be a focus in dementia

In the past, “agitation” in the context of the dementias referred to a wide range of...

Alzheimer's Disease

Read time: 4 min

The promise of person-centered care

Postponing the need for admission to an institution, and improving quality of life within it...

Read time: 2 min

Value of Treatment: European Brain Council publishes landmark report

Greater clinical benefit for patients and gains in cost-effectiveness for society -- both can be...

Depression, Schizophrenia

Read time: 2 min

Congress highlights

Sexual side-effects – let’s talk!

Sexual side-effects, sometimes experienced by patients during treatment, are not only debilitating...

Read time: 3 min

Congress highlights

Finding the sweet spot for pharmacotherapy in schizophrenia

Over recent years, the goals in the management of patients with schizophrenia have evolved from...

Read time: 4 min

Satellite symposium

Remission of depression from the patient’s perspective

Clinicians say a person is in remission, but would that patient agree? What do patients look...

Read time: 4 min

Congress highlights

Keeping a healthy brain

Preventing the long-term consequences of schizophrenia, and particularly of multiple relapses, is...

Read time: 2 min

Treatment goals and challenges in depression - a New Zealand doctor’s perspective

Dr Teresa Fontillas-Luis works in an acute psychiatric unit in New Zealand. At ENCP 2017, Dr...

Alzheimer's Disease

Read time: 4 min

Congress highlights

Moves towards better management of agitation

Ninety percent of people with Alzheimer’s experience at least one clinically significant...

Country selection

We are registering that you are located in Brazil - if that's correct then please continue to Progress in Mind Brazil

Not located in Brazil?
Go to a different regional HUB

Continue to Progress in Mind Continue to Progress in Mind Brazil Continue to Progress in Mind Spain Continue to Progress in Mind Italy Continue to Progress in Mind

You are leaving Progress in Mind

Continue to

Cancel

Hello
Please confirm your email

We have just sent you an email, with a confirmation link.
Before you can gain full access - you need to confirm your email.

The information on this site is exclusively intented for health care professionals.

All the information included in the Website is related to products of the local market and, therefore, directed to health professionals legally authorized to prescribe or dispense medications with professional practice. The technical information of the drugs is provided merely informative, being the responsibility of the professionals authorized to prescribe drugs and decide, in each concrete case, the most appropriate treatment to the needs of the patient.

Accept

Decline

Congress

Register for access to Progress in Mind in your country